Xinhong Wu
Overview
Explore the profile of Xinhong Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, Zhang Q, Sun T, Li H, Cheng Y, Tong Z, et al.
Cancer Commun (Lond)
. 2025 Feb;
PMID: 40013319
Background: Bireociclib (XZP-3287) is a novel selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT-1 aimed to further...
2.
Wu X, Yuan F, Guo L, Gao D, Zheng W, Chen C, et al.
BMC Cancer
. 2025 Feb;
25(1):285.
PMID: 39966717
Triple-negative breast cancer (TNBC) is traditionally treated with systemic chemotherapy, often resulting in significant off-target toxicity. In this study, we assess the efficacy of intraductal chemotherapeutic delivery, aimed at reducing...
3.
Xu B, Zhang Q, Luo Y, Tong Z, Sun T, Shan C, et al.
Nat Commun
. 2025 Jan;
16(1):716.
PMID: 39820749
Lerociclib (GB491), a highly selective oral CDK4/6 inhibitor, has displayed anti-tumor activity and differentiated safety and tolerability profile in previous ph1/2 clinical trials. The LEONARDA-1, a randomized, double-blind, phase III...
4.
Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, et al.
Future Oncol
. 2024 Dec;
21(4):421-429.
PMID: 39628303
No abstract available.
5.
Li J, Wu X, Yan S, Shen J, Tong T, Aslam M, et al.
Mol Neurobiol
. 2024 Oct;
62(4):4221-4236.
PMID: 39422855
Depression is recognized globally as one of the most intractable diseases, and its complexity and diversity make treatment extremely challenging. Acupuncture has demonstrated beneficial effects in various psychiatric disorders. However,...
6.
Wu X, Ibrahim N, Liang Y, Liu X
Microorganisms
. 2024 Jun;
12(6).
PMID: 38930470
The extensive harvesting of , as a biomedicinal plant and a wild source of quaternary benzo[c]phenanthridine alkaloids, has led to a rapid decline in its population. An alternative approach to...
7.
Shao Z, Cai L, Wang S, Hu X, Shen K, Wang H, et al.
Discov Oncol
. 2024 Jun;
15(1):237.
PMID: 38904918
Background: The global BOLERO-2 trial established the efficacy and safety of combination everolimus (EVE) and exemestane (EXE) in the treatment of estrogen receptor positive (ER +), HER2-, advanced breast cancer...
8.
Yao H, Yan M, Tong Z, Wu X, Ryu M, Park J, et al.
J Clin Oncol
. 2024 Jun;
42(29):3453-3465.
PMID: 38900984
Purpose: SHR-A1811 is an antibody-drug conjugate composed of an anti-human epidermal growth factor receptor 2 (HER2) antibody trastuzumab, a cleavable linker, and a topoisomerase I inhibitor payload. We assessed the...
9.
Zhang Q, Ouyang Q, Li W, Chiu J, Yan M, Lu Y, et al.
Transl Breast Cancer Res
. 2024 May;
3:31.
PMID: 38751523
Background: Trastuzumab is the recommended first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) patients in China, but therapeutic resistance to trastuzumab and other early-line...
10.
Zheng H, Wu X, Guo L, Liu J
Front Oncol
. 2024 Feb;
14:1336696.
PMID: 38347830
MyD88 plays a central role in breast cancer, exerting a multitude of effects that carry substantial implications. Elevated MyD88 expression is closely associated with aggressive tumor characteristics, suggesting its potential...